|
1
|
European Network of Cancer Registries.
Eurocim version 4.0: European incidence database V2.3, 730 entity
dictionary. Lyon: 2001
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chow WH, Dong LM and Devesa S:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adeghate E, Schattner P and Dunn E: An
update on the etiology and epidemiology of diabetes mellitus. Ann
NY Acad Sci. 1084:1–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moyad MA: Review of potential risk factors
for kidney (renal cell) cancer. Semin Urol Oncol. 19:280–293.
2001.
|
|
7
|
Lindblad P, Chow WH, Chan J, Bergström A,
Wolk A, Gridley G, McLaughlin JK, Nyrén O and Adami HO: The role of
diabetes mellitus in the aetiology of renal cell cancer.
Diabetologia. 42:107–112. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zucchetto A, Dal Maso L, Tavani A,
Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A,
Negri E, Franceschi S and La Vecchia C: History of treated
hypertension and diabetes mellitus and risk of renal cell cancer.
Ann Oncol. 18:596–600. 2007. View Article : Google Scholar
|
|
9
|
Habib SL, Prihoda TJ, Luna M and Werner
SA: Diabetes and risk of renal cell carcinoma. J Cancer. 3:42–48.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joh HK, Willett WC and Cho E: Type 2
diabetes and the risk of renal cell cancer in women. Diabetes Care.
34:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Inoue M, Iwasaki M, Otani T, Sasazuki S,
Noda M and Tsugane S: Diabetes mellitus and the risk of cancer:
Results from a large-scale population-based cohort study in Japan.
Arch Intern Med. 166:1871–1877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Süer E, Oztürk E, Gülpınar O, Kayış A and
Baltacı S: Effect of type 2 diabetes mellitus on prognosis of
nonmetastatic renal cell cancer. Korean J Urol. 54:499–503. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antonelli A, Arrighi N, Corti S, Zanotelli
T, Cozzoli A, Cosciani Cunico S and Simeone C: Pre-existing type-2
diabetes is not an adverse prognostic factor in patients with renal
cell carcinoma: A single-center retrospective study. Urol Oncol.
31:1310–1315. 2013. View Article : Google Scholar
|
|
14
|
Lee S, Hong SK, Kwak C, Kim HH and Lee SE:
Prognostic significance of diabetes mellitus in localized renal
cell carcinoma. Jpn J Clin Oncol. 42:318–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vavallo A, Simone S, Lucarelli G,
Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna
M, Cariello M, Ranieri E, et al: Pre-existing type 2 diabetes
mellitus is an independent risk factor for mortality and
progression in patients with renal cell carcinoma. Medicine
(Baltimore). 93:e1832014. View Article : Google Scholar
|
|
16
|
Chen L, Li H, Gu L, Ma X, Li X, Gao Y,
Zhang Y, Shen D, Fan Y, Wang B, et al: The impact of diabetes
mellitus on renal cell carcinoma prognosis: A meta-analysis of
cohort studies. Medicine (Baltimore). 94:e10552015. View Article : Google Scholar
|
|
17
|
Lee H, Kwak C, Kim HH, Byun SS, Lee SE and
Hong SK: Diabetes mellitus as an independent predictor of survival
of patients surgically treated for renal cell carcinoma: A
propensity score matching study. J Urol. 194:1554–1560. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fukushima H, Masuda H, Yokoyama M,
Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F,
Saito K, et al: Diabetes mellitus with obesity is a predictor of
recurrence in patients with non-metastatic renal cell carcinoma.
Jpn J Clin Oncol. 43:740–746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calle EE and Kaaks R: Overweight, obesity
and cancer: Epidemiological evidence and proposed mechanisms. Nat
Rev Cancer. 4:579–591. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Renehan AG, Roberts DL and Dive C: Obesity
and cancer: Pathophysiological and biological mechanisms. Arch
Physiol Biochem. 114:71–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lowrance WT, Thompson RH, Yee DS, Kaag M,
Donat SM and Russo P: Obesity is associated with a higher risk of
clear-cell renal cell carcinoma than with other histologies. BJU
Int. 105:16–20. 2010. View Article : Google Scholar :
|
|
22
|
Callewaert PR, Van Poppel H,
Vanderschueren D and Baert L: Uncontrollable diabetes mellitus: A
rare paraneoplastic manifestation of renal cell carcinoma. Nephrol
Dial Transplant. 14:2263–2264. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho M, Shim H and Park MR: Hypoglycemic
coma in a patient with metastatic renal cell carcinoma treated with
sunitinib. Korean J Med. 87:501–504. 2014. View Article : Google Scholar
|
|
24
|
Louvet C, Szot GL, Lang J, Lee MR,
Martinier N, Bollag G, Zhu S, Weiss A and Bluestone JA: Tyrosine
kinase inhibitors reverse type 1 diabetes in nonobese diabetic
mice. Proc Natl Acad Sci USA. 105:18895–18900. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agostino NM, Chinchilli VM, Lynch CJ,
Koszyk-Szewczyk A, Gingrich R, Sivik J and Drabick JJ: Effect of
the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib,
and imatinib) on blood glucose levels in diabetic and nondiabetic
patients in general clinical practice. J Oncol Pharm Pract.
17:197–202. 2011. View Article : Google Scholar
|
|
26
|
Billemont B, Medioni J, Taillade L, Helley
D, Meric JB, Rixe O and Oudard S: Blood glucose levels in patients
with metastatic renal cell carcinoma treated with sunitinib. Br J
Cancer. 99:1380–1382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Böhm S, Hess D, Gillessen S and Brändle M:
Improved glycemic control with the multi-receptor tyrosine kinase
inhibitor pazopanib. Diabetes Care. 33:e822010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee Y, Jung HS, Choi HJ, Kim MJ, Kim TM,
Park KS and Kim SY: Life-threatening hypoglycemia induced by a
tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A
case report. Diabetes Res Clin Pract. 93:e68–e70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oh JJ, Hong SK, Joo YM, Lee BK, Min SH,
Lee S, Byun SS and Lee SE: Impact of sunitinib treatment on blood
glucose levels in patients with metastatic renal cell carcinoma.
Jpn J Clin Oncol. 42:314–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Imarisio I, Paglino C, Ganini C, Magnani
L, Caccialanza R and Porta C: The effect of sorafenib treatment on
the diabetic status of patients with renal cell or hepatocellular
carcinoma. Future Oncol. 8:1051–1057. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huda MSB, Amiel SA, Ross P and Aylwin SJ:
Tyrosine kinase inhibitor sunitinib allows insulin independence in
long-standing type 1 diabetes. Diabetes Care. 37:e87–e88. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tyrrell HE and Pwint T: Sunitinib and
improved diabetes control. BMJ Case Rep. 2014:2014.PubMed/NCBI
|
|
33
|
Szałek E, Karbownik A, Sobańska K,
Grabowski T, Połom W, Lewandowska M, Wolc A, Matuszewski M and
Grześkowiak E: The pharmacokinetics and hypoglycaemic effect of
sunitinib in the diabetic rabbits. Pharmacol Rep. 66:892–896. 2014.
View Article : Google Scholar
|
|
34
|
Holstein A, Kovacs P and Beil W: Severe
hypoglycemia due to possible interaction between glibenclamide and
sorafenib in a patient with hepatocellular carcinoma. Curr Drug
Saf. 8:148–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Demirci A, Bal O, Durnali A, Ekinci AŞ,
Eşbah O, Alkiş N and Oksüzoğlu B: Sunitinib-induced severe
hypoglycemia in a diabetic patient. J Oncol Pharm Pract.
20:469–472. 2014. View Article : Google Scholar
|
|
36
|
Fountas A, Tigas S, Giotaki Z, Petrakis D,
Pentheroudakis G and Tsatsoulis A: Severe resistant hypoglycemia in
a patient with a pancreatic neuroendocrine tumor on sunitinib
treatment. Hormones (Athens). 14:438–441. 2015.
|
|
37
|
Thijs AM, Tack CJ, van der Graaf WT,
Rongen GA and van Herpen CM: The early effect of sunitinib on
insulin clearance in patients with metastatic renal cell carcinoma.
Br J Clin Pharmacol. 81:768–772. 2016. View Article : Google Scholar
|
|
38
|
Holmes G, Galitz L, Hu P and Lyness W:
Pharmacokinetics of insulin aspart in obesity, renal impairment or
hepatic impairment. Br J Clin Pharmacol. 60:469–476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kulozik F and Hasslacher C: Insulin
requirements in patients with diabetes and declining kidney
function: differences between insulin analogues and human insulin?
Ther Adv Endocrinol Metab. 4:113–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lodish MB and Stratakis CA: Endocrine side
effects of broad-acting kinase inhibitors. Endocr Relat Cancer.
17:R233–R244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guevremont C, Alasker A and Karakiewicz
PI: Management of sorafenib, sunitinib, and temsirolimus toxicity
in metastatic renal cell carcinoma. Curr Opin Support Palliat Care.
3:170–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ryu TY, Park J and Scherer PE:
Hyperglycemia as a risk factor for cancer progression. Diabetes
Metab J. 38:330–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Habib SL and Liang S: Hyperactivation of
Akt/mTOR and deficiency in tuberin increased the oxidative DNA
damage in kidney cancer patients with diabetes. Oncotarget.
5:2542–2550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chitnis MM, Yuen JS, Protheroe AS, Pollak
M and Macaulay VM: The type 1 insulin-like growth factor receptor
pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ouban A, Muraca P, Yeatman T and Coppola
D: Expression and distribution of insulin-like growth factor-1
receptor in human carcinomas. Hum Pathol. 34:803–808. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aleksic T, Chitnis MM, Perestenko OV, Gao
S, Thomas PH, Turner GD, Protheroe AS, Howarth M and Macaulay VM:
Type 1 insulin-like growth factor receptor translocates to the
nucleus of human tumor cells. Cancer Res. 70:6412–6419. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lkhagvadorj S, Oh SS, Lee MR, Jung JH,
Chung HC, Cha SK and Eom M: Insulin receptor expression in clear
cell renal cell carcinoma and its relation to prognosis. Yonsei Med
J. 55:861–870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rasmuson T, Grankvist K, Jacobsen J,
Olsson T and Ljungberg B: Serum insulin-like growth factor-1 is an
independent predictor of prognosis in patients with renal cell
carcinoma. Acta Oncol. 43:744–748. 2004. View Article : Google Scholar
|
|
50
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
Overview and recent insights. Endocr Rev. 28:20–47. 2007.
View Article : Google Scholar
|
|
51
|
Hägerkvist R, Makeeva N, Elliman S and
Welsh N: Imatinib mesylate (Gleevec) protects against
streptozotocin-induced diabetes and islet cell death in vitro. Cell
Biol Int. 30:1013–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mokhtari D, Li T, Lu T and Welsh N:
Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB
activation and chemokine production in vitro. PLoS One.
6:e248312011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Welsh N: Does the small tyrosine kinase
inhibitor Imatinib mesylate counteract diabetes by affecting
pancreatic islet amyloidosis and fibrosis? Expert Opin Investig
Drugs. 21:1743–1750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ono K, Suzushima H, Watanabe Y, Kikukawa
Y, Shimomura T, Furukawa N, Kawaguchi T and Araki E: Rapid
Amelioration of hyperglycemia facilitated by dasatinib in a chronic
myeloid leukemia patient with type 2 diabetes mellitus. Intern Med.
51:2763–2766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu H, Barnes GT, Yang Q, Tan G, Yang D,
Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA and Chen H:
Chronic inflammation in fat plays a crucial role in the development
of obesity-related insulin resistance. J Clin Invest.
112:1821–1830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Weisberg SP, McCann D, Desai M, Rosenbaum
M, Leibel RL and Ferrante AW Jr: Obesity is associated with
macrophage accumulation in adipose tissue. J Clin Invest.
112:1796–1808. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gordon S and Martinez FO: Alternative
activation of macrophages: Mechanism and functions. Immunity.
32:593–604. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gregor MF and Hotamisligil GS:
Inflammatory mechanisms in obesity. Annu Rev Immunol. 29:415–445.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Prada PO, Ropelle ER, Mourão RH, de Souza
CT, Pauli JR, Cintra DE, Schenka A, Rocco SA, Rittner R, Franchini
KG, et al: EGFR tyrosine kinase inhibitor (PD153035) improves
glucose tolerance and insulin action in high-fat diet-fed mice.
Diabetes. 58:2910–2919. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hägerkvist R, Jansson L and Welsh N:
Imatinib mesylate improves insulin sensitivity and glucose disposal
rates in rats fed a high-fat diet. Clin Sci (Lond). 114:65–71.
2008. View Article : Google Scholar
|
|
61
|
Han MS, Chung KW, Cheon HG, Rhee SD, Yoon
CH, Lee MK, Kim KW and Lee MS: Imatinib mesylate reduces
endoplasmic reticulum stress and induces remission of diabetes in
db/db mice. Diabetes. 58:329–336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar
|
|
63
|
Jäger D, Ma JH, Mardiak J, Ye DW,
Korbenfeld E, Zemanova M, Ahn H, Guo J, Leonhartsberger N, Stauch
K, et al: Sorafenib treatment of advanced renal cell carcinoma
patients in daily practice: The large international PREDICT study.
Clin Genitourin Cancer. 13:156–64.e1. 2015. View Article : Google Scholar
|
|
64
|
Mokhtari D and Welsh N: Potential utility
of small tyrosine kinase inhibitors in the treatment of diabetes.
Clin Sci (Lond). 118:241–247. 2009. View Article : Google Scholar
|
